Stock Research: SK Biopharmaceuticals

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

SK Biopharmaceuticals

KOSE:A326030 KR7326030004
16
  • Value
    12
  • Growth
    80
  • Safety
    Safety
    6
  • Combined
    8
  • Sentiment
    49
  • 360° View
    360° View
    16
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

SK Biopharmaceuticals Co Ltd is a Korea-based pharmaceutical company focused on the development and manufacture of drugs. The company operates in the pharmaceutical industry, developing and producing epilepsy drugs, sleep disorder drugs, rare neurological disorder drugs, concentration disorder drugs, schizophrenia drugs, bipolar disorder drugs, and new drug development. The company is based in Korea. In the last fiscal year, the company had a market cap of $5509 millions, profits of $342 millions, and revenue of $371 millions.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 16 (better than 16% compared with alternatives), overall professional sentiment and financial characteristics for the stock SK Biopharmaceuticals are critical, mostly below average. The 360° View is based on consolidating four consolidated indicators, with three out of four indicators below average for SK Biopharmaceuticals. The consolidated Growth Rank has a good rank of 80, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. It ranks higher than 80% of competitors in the same industry. The other indicators are below average, namely the Value, Safety, and Sentiment Ranks.The Value Rank at 6 means that the share price of SK Biopharmaceuticals is on the high side compared with its peers regarding revenues, profits, and invested capital. The stock price is higher than for 94% of alternative stocks in the same industry. The consolidated Safety Rank has a riskier rank of 12, which means that the company has a riskier financing structure than 88% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. The consolidated Sentiment Rank also has a low rank of 49, indicating professional investors are more pessimistic about the stock than for 51% of alternative investment opportunities. ...read more

more
Index
KOSPI
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 2-Oct-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
6 1 1 1
Growth
80 82 100 93
Safety
Safety
12 4 6 22
Sentiment
49 88 59 52
360° View
360° View
16 35 27 25
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
67 60 63 59
Opinions Change
69 50 55 50
Pro Holdings
n/a 78 30 22
Market Pulse
58 82 84 70
Sentiment
49 88 59 52
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
6 1 1 1
Growth
80 82 100 93
Safety Safety
12 4 6 22
Combined
8 7 16 30
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
15 7 1 1
Price vs. Earnings (P/E)
7 5 1 3
Price vs. Book (P/B)
3 1 1 3
Dividend Yield
1 1 1 1
Value
6 1 1 1
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
96 98 98 81
Profit Growth
16 6 81 88
Capital Growth
86 60 73 91
Stock Returns
66 88 85 9
Growth
80 82 100 93
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
31 19 19 70
Refinancing
14 6 15 11
Liquidity
37 10 6 1
Safety Safety
12 4 6 22

Similar Stocks

Discover high‑ranked alternatives to SK Biopharmaceuticals and broaden your portfolio horizons.

Japan Airlines

TSE:9201
Country: Japan
Industry: Airlines
Size: X-Large
Full Stock Analysis

AMOREPACIFIC

KOSE:A002790
Country: South Korea
Industry: Personal Products
Size: Medium
Full Stock Analysis

NH Investment & Securities

KOSE:A005940
Country: South Korea
Industry: Investment Banking & Brokerage
Size: Medium
Full Stock Analysis

Hisamitsu Pharmaceutical

TSE:4530
Country: Japan
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.